Welcome to our dedicated page for Nutriband news (Ticker: NTRBW), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Overview of Nutriband Inc.
Nutriband Inc. (NASDAQ: NTRB, NASDAQ: NTRBW) is a U.S.-based pharmaceutical company headquartered in Oviedo, Florida. The company specializes in the development of innovative transdermal drug delivery systems, with a primary focus on addressing the global opioid crisis through its proprietary AVERSA™ abuse-deterrent technology. This technology is designed to incorporate aversive agents into transdermal patches to prevent the abuse, misuse, diversion, and accidental exposure of drugs with high abuse potential, such as opioids.
Core Technology: AVERSA™
The cornerstone of Nutriband’s operations is its patented AVERSA™ technology, which employs a proprietary aversive agent coating to deter oral abuse and accidental exposure. This innovation is particularly significant for transdermal drugs like fentanyl, which carry a high risk of misuse. The AVERSA™ platform has broad applications and can be integrated into various transdermal patches, enhancing the safety profile of essential medications while ensuring accessibility for patients in need.
Key Product: AVERSA™ Fentanyl
The company’s lead product under development is AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system. This product aims to be the world’s first abuse-deterrent opioid patch, addressing the dual challenges of opioid misuse and accidental exposure. AVERSA™ Fentanyl is being developed in collaboration with Kindeva Drug Delivery, a leading global contract development and manufacturing organization. The product is advancing through the U.S. FDA’s streamlined 505(b)(2) NDA regulatory pathway, which requires minimal clinical trials, potentially accelerating its time to market.
Intellectual Property and Global Reach
Nutriband’s AVERSA™ technology is protected by an extensive international intellectual property portfolio, with patents issued in 46 countries, including the United States, Europe, Japan, Korea, Russia, China, Canada, and Australia. This robust patent coverage positions the company to commercialize its technology on a global scale, ensuring competitive advantages in major pharmaceutical markets.
Revenue Streams and Market Presence
In addition to its pharmaceutical innovations, Nutriband generates revenue through its wholly-owned subsidiary, Pocono Pharma, which offers contract manufacturing services. The subsidiary specializes in kinesiology tape and other consumer transdermal products, supplying major retail chains such as Target, Walmart, Walgreens, and CVS. This diversified revenue model strengthens the company’s financial foundation while supporting its core R&D initiatives.
Strategic Collaborations
Nutriband has established strategic partnerships to advance its product pipeline. Its collaboration with Kindeva Drug Delivery ensures the scalability and commercial manufacturing capabilities required for AVERSA™ Fentanyl. Additionally, the company has licensed the use of Bitrex®, the world’s most bitter substance, as an aversive agent in its abuse-deterrent patches, further enhancing the effectiveness of its technology.
Market Significance
By addressing critical issues such as opioid misuse and accidental exposure, Nutriband positions itself as a key player in the abuse-deterrent pharmaceutical segment. The global market for such technologies is growing, driven by increasing regulatory focus on opioid safety and the need for innovative solutions to combat the opioid crisis. Nutriband’s AVERSA™ technology not only meets these demands but also sets a new standard for safety in transdermal drug delivery.
Conclusion
Nutriband Inc. is at the forefront of pharmaceutical innovation, leveraging its AVERSA™ technology to enhance patient safety and address pressing public health challenges. With its strong intellectual property portfolio, strategic collaborations, and diversified revenue streams, the company is well-positioned to make a significant impact in the pharmaceutical industry, particularly in the realm of abuse-deterrent drug delivery systems.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) is showcasing its innovations at the 2023 Transdermal and Microneedle Conference in London on January 23-24, 2023. CEO Gareth Sheridan will present on January 24 at 11:00 a.m. GMT, focusing on enhancing transdermal technologies to minimize liability regarding abusable medications. COO Dr. Alan Smith will join a panel discussion at 11:40 a.m. GMT about microneedle applications in drug delivery. The conference will also feature industry leaders including Merck and GSK. Nutriband's AVERSA technology aims to prevent drug abuse, emphasizing safety in chronic pain treatments.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has dual-listed on Upstream, a platform for digital securities and NFTs, enhancing its accessibility to global investors. The listing became effective on January 5, 2023, allowing trades in real-time through Upstream's transparent order book. A commemorative NFT for this listing is also available. CEO Gareth Sheridan emphasized the listing's value for shareholders and the company’s mission to reach a modern investor base. However, U.S. investors are only allowed to liquidate existing holdings on Upstream.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has announced its dual listing on Upstream, commencing January 5, 2023. This move positions Nutriband as the first company to utilize Upstream's platform, allowing global investors to trade using various payment methods, including USDC digital currency. The dual listing aims to enhance liquidity, price discovery, and accessibility for U.S. investors. Nutriband's primary focus is developing transdermal pharmaceutical products, notably an abuse deterrent fentanyl patch utilizing AVERSA™ technology, which is crucial for preventing drug abuse.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has commenced production of its AI Tape brand, with an anticipated launch in Q1 2023. The new product aims to enhance traditional Kinesiology Tape by incorporating therapeutic ingredients in a proprietary adhesive mix. Production is taking place at the company's facility in North Carolina. Nutriband focuses on transdermal pharmaceutical products, developing an abuse deterrent fentanyl patch using its AVERSA™ technology. This aims to prevent drug misuse and accidental exposure.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has announced its approval for a dual listing on Upstream, with trading set to begin on January 5, 2023. This move aims to enhance liquidity and broaden its investor base by allowing trading in digital currencies like USDC and traditional payment methods. Participants will also receive a commemorative NFT on listing day. CEO Gareth Sheridan highlighted that this listing will facilitate reaching international markets and bolster shareholder value as the company develops its AVERSA™ technology for transdermal products.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) will feature on The RedChip Money Report on Bloomberg TV, airing December 17, 2022, at 7 p.m. ET. The interview will showcase Nutriband's transdermal technology and its applications, led by Chief Scientific Officer Dr. Jeff Patrick. This technology includes the development of an abuse deterrent fentanyl patch utilizing AVERSA™ technology. The segment will be accessible to an estimated 73 million U.S. homes. For full access to the interview, visit here.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) reported a record revenue of $620,000 for Q3 2022, marking a 118% increase from Q3 2021. Year-to-date revenue reached $1,552,074, a 67% year-over-year growth. The company continues to expand its AVERSA™ intellectual property portfolio with patents granted in 44 countries. Net loss decreased to $1.07 million from $1.57 million in the prior year. CEO Gareth Sheridan highlighted potential peak sales for AVERSA Fentanyl could range between $80 million to $200 million.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that CEO Gareth Sheridan will present at the RHK Capital Disruptive Growth Conference on December 5, 2022, at 10:20 AM in New York City. The presentation will focus on the company's AVERSA technology and its market potential. The conference will host executives from up to 30 growth-oriented companies, engaging with institutional investors and financial advisors. Nutriband specializes in transdermal pharmaceutical products, with a lead product under development being an abuse deterrent fentanyl patch utilizing AVERSA technology.
Nutriband Inc. (NTRB, NTRBW) announced the granting of Canadian patent No. 2,937,649 for its AVERSA™ transdermal abuse deterrent technology. The patent issued on November 1, 2022, enhances protection for the AVERSA™ products across North America, following similar patents granted in the U.S. and Mexico. This technology aims to mitigate opioid abuse, particularly in light of Canada's opioid crisis. Nutriband's AVERSA™ Fentanyl system is projected to achieve peak U.S. sales between $80M and $200M, addressing a significant public health issue while ensuring patient access.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) endorses the 2022 CDC guidelines on opioid prescribing, emphasizing the need for abuse deterrent technologies in pain management. The new guidelines allow greater opioid access for those with chronic pain while recognizing the challenges of the prior restrictions. Nutriband's AVERSA™ technology aims to mitigate abuse risks associated with transdermal opioids. The lead product, AVERSA™ Fentanyl, is projected to generate $80M - $200M in potential annual sales post-launch, enhancing safety for vulnerable patient groups.
FAQ
What is the current stock price of Nutriband (NTRBW)?
What does Nutriband Inc. specialize in?
What is AVERSA™ technology?
What is Nutriband’s lead product?
Where is Nutriband’s technology patented?
How does Nutriband generate revenue?
Who are Nutriband’s strategic partners?
What challenges does Nutriband face?
What makes Nutriband unique in the pharmaceutical industry?
